Treatment of Alzheimer's disease: Current status and new perspectives

Lancet Neurology

Volumn 2, Issue 9, 2003, Pages 539-547

  Scarpini, Elio ^a   Scheltens, Philip ^b   Feldman, Howard ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; ANTIINFLAMMATORY AGENT; BETA SECRETASE INHIBITOR; CELECOXIB; CHOLINESTERASE INHIBITOR; DONEPEZIL; ENZYME INHIBITOR; GALANTAMINE; GAMMA SECRETASE INHIBITOR; HYDROXYCHLOROQUINE; HYPOCHOLESTEROLEMIC AGENT; IBUPROFEN; INDOMETACIN; MEMANTINE; METAL CHELATE; NAPROXEN; NCX 2216; NIMESULIDE; NOOTROPIC AGENT; PREDNISONE; RIVASTIGMINE; ROFECOXIB; SULINDAC; TACRINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; CHOLINERGIC SYSTEM; CLINICAL TRIAL; COCHRANE LIBRARY; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; NEUROTRANSMISSION; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; VACCINATION;

EID: 0042020173     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(03)00502-7     Document Type: Review

References (119)

1. Bartus R.T., Dean R.L., Beer B., et al. The cholinergic hypothesis of geriatric memory dysfunction. Science. 217:1982;408-414.
2. Perry E.K. The cholinergic hypothesis ten years on. Br Med Bull. 42:1986;63-69.
3. Bowen D.M., Francis P.T., Pangalos M.N., et al. Treatment strategies for Alzheimer's disease. Lancet. 339:1992;132-133.
4. Whitehouse P.J., Martino A.M., Antuono P.G., et al. Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Res. 371:1986;146-151.
5. Newhouse P.A., Potter A., Levin E.D. Nicotinic acetylcholine involvement in Alzheimer's and Parkinson's disease: implications for therapeutics. Drugs Aging. 11:1997;206-228.
6. Winkler J., Thal L.J., Gage F.H., et al. Cholinergic strategies for Alzheimer's disease. J Mol Med. 76:1998;555-567.
7. Davis K.L., Mohs R.C., Marin D., et al. Cholinergic markers in elderly patients with early signs of Alzheimer's disease. JAMA. 281:1999;1401-1406.
8. Dekosky S.T., Ikonomovic M.D., Styren S.D., et al. Upregulation of choline acetyltransferase in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol. 51:2002;144-155.
9. Mufson E.J., Ma S.Y., Cochran E.J., et al. Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer's disease. J Comp Neurol. 427:2000;19-30.
10. Doody R.S., Stevens J.C., Beck C., et al. Practice parameter: management of dementia (an evidence-based review). Neurology. 56:2001;1154-1166.
11. Rogers S.L., Farlow M.R., Doody R.S., et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology. 50:1998;136-145.
12. Corey-Bloom J., Anand R., Veach J., et al. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatr Psychopharmacol. 1:1998;55-65.
13. Tariot P.N., Solomon P.R., Morris J.C., et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology. 54:2000;2269-2276.
14. Cummings J.L. Cholinesterase inhibitors: a new class of psychotropic agents. Am J Psychiatry. 157:2000;4-15.
15. Scott L., Goa K. Galantamine: a review of its use in Alzheimer's Disease. Drugs. 60:2000;1095-1122.
16. Perry E.K., Perry R.H., Blessed G., et al. Changes in brain cholinesterases in senile dementia of Alzheimer's type. Neuropathol Appl Neurobiol. 4:1978;273-277.
17. Arendt T., Bruckner M.K., Lange M., et al. Changes in acetylcholinesterases and butyrylcholinesterases in Alzheimer's disease resemble embryonic development: a study of molecular forms. Neurochem Int. 21:1992;381-396.
18. Xie W., Stribley J.A., Chatonnet A., et al. Postnatal developmental delay and supersensitivity to organophosphate in gene-targeted mice lacking acetylcholinesterase. J Pharmacol Exp Ther. 293:2000;896-902.
19. Nordberg A., Svensson A.L. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology. Drug Saf. 19:1998;465-480.
20. Jann M.W., Shirley K.L., Small G.W. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet. 41:2002;719-739.
21. Birks J., Melzer D., Beppu H. Donepezil for mild and moderate Alzheimer's disease (Cochrane Review). The Cochrane Library. 2002;Update Software, Oxford. Issue 3.
22. Birks J., Grimley Evans J., Iakovidou V., et al. Rivastigmine for Alzheimer's disease (Cochrane Review). The Cochrane Library. 2002;Update Software, Oxford. Issue 3.
23. Olin J., Schneider L. Galantamine for Alzheimer's disease (Cochrane Review). The Cochrane Library. 2002;Update Software, Oxford. Issue 3.
24. Winblad B., Engedal K., Soininen H., et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 57:2001;489-495.
25. Feldman H., Gauthier S., Hecker J., et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology. 57:2001;613-620.
26. Wilkinson D.G., Passmore A.P., Bullock R., et al. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease. Int J Clin Pract. 56:2002;441-446.
27. Jones RW, Passmore P, Wetterberg P, et al. First head-to-head study comparing the tolerability and efficacy of donepezil and galantamine in Alzheimer's disease. Presented as poster at the 7th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy, April 3-6 2002, Geneva, Switzerland.
28. McKeith I., Truyen L., Lilienfeld S., Mahableshwarkar A. Galantamine demonstrates superior efficacy on attention and MMSE compared with donepezil in patients with Alzheimer's disease actively treated for 52 weeks: an initial analysis. Neurology. 60:(suppl 5):2003;A141.
29. Auriacombe S., Pere J.J., Loria-Kanza Y., et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil. Curr Med Res Opin. 18:2002;129-138.
30. Emre E. Switching cholinesterase inhibitors in patients with Alzheimer's disease. Int J Clin Pract. 127:2002;64-72.
31. Ferris S.H. Switching previous therapies for Alzheimer's disease to galantamine. Clin Ther. 23:(suppl A):2001;A3-A7.
32. Sucher N.J., Awobuluyi M., Choi Y.B., et al. NMDA receptors: from genes to channels. Trends Pharmacol Sci. 17:1996;348-355.
33. Bliss T.V., Collinridge G.L. A synaptic model of memory: long term potentiation in the hippocampus. Nature. 361:1993;31-39.
34. Greenamyre J.T., Porter R.H. Anatomy and physiology of glutamate in the CNS. Neurology. 44:(suppl 8):1994;S7-S13.
35. Greenamyre J.T., Young A.B. Excitatory amino acids and Alzheimer's disease. Neurobiol Aging. 10:1989;593-602.
36. Winblad B., Poritis N. Memantine in severe dementia: results of the M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiat. 14:1999;135-146.
37. Reinsberg B., Doody R., Stoffer A., et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 348:2003;1333-1341.
38. Farlow M.R., Tariot P.N., Grossberg G.T., et al. Memantine/donepezil dual therapy is superior to placebo/donepezil therapy for treatment of moderate to severe AD. Neurology. 60:(suppl 1):2003;A412.
39. Areosa Sastre A., Sherriff F. Memantine for Dementia (Cochrane Review). The Cochrane Library. 2003;Update Software, Oxford. Issue 1.
40. Selkoe D.J. Presenilin, Notch, and the genesis and treatment of Alzheimer's disease. Proc Natl Acad Sci. 98:2001;11039-11041.
41. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 297:2002;353-356.
42. Lee R.K., Wurtman R.J., Cox A.J., et al. Amyloid precursor protein processing is stimulated by metabotropic glutamate receptors. Proc Natl Acad Sci. 17:1995;8083-8087.
43. Esler W.P., Wolfe M.S. A portrait of Alzheimer secretases-new features and familiar faces. Science. 293:2001;1449-1454.
44. Sisodia S.S., St George-Hyslop P.H. Gamma-Secretase, Notch, Abeta and Alzheimer's disease: where do the presenilins fit in? Nat Rev Neurosci. 3:2002;281-290.
45. Dewachter I., Van Leuven F. Secretases as targets for the treatment of Alzheimer's disease: the prospects. Lancet Neurology. 1:2002;409-416.
46. Golde T.E., Younkin S.G. Presenilins as therapeutic targets for the treatment of Alzheimer's disease. Trends Mol Med. 6:2001;264-269.
47. Cai H., Wang Y., McCarthy D., et al. BACE1 is the major β secretase for generation of Aβ peptides by neurons. Nat Neurosci. 4:2001;233-234.
48. Luo Y., Bolon B., Kahn S., et al. Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation. Nat Neurosci. 4:2001;231-232.
49. Petit A., Bihel F., Alves da Costa C., et al. New protease inhibitors prevent gamma-secretase-mediated production of Abeta40/42 without affecting Notch cleavage. Nat Cell Biol. 3:2001;507-511.
50. Yu G., Nishimura M., Arawaka S., et al. Nicastrin modulates presenilin-mediated notch/glp-1 signal transduction and betaAPP processing. Nature. 407:2000;48-54.
51. Dovey H.F., John V., Anderson J.P., et al. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem. 76:2001;173-181.
52. Schenk D., Barbour R., Dunn W., et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 400:1999;173-177.
53. Games D., Adams D., Alessandrini R., et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature. 373:1995;523-527.
54. Weiner H.L., Lemere C.A., Maron R., et al. Nasal administration of amyloid- peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Ann Neurol. 48:2000;567-579.
55. Bard F., Cannon C., Barbour R., et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer's disease. Nat Med. 6:2000;916-919.
56. DeMattos R.B., Bales K.R., Cummins D.J., et al. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci. 98:2001;8850-8855.
57. Janus C., Pearson J., McLaurin J., et al. A β-peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature. 408:2000;979-982.
58. Morgan D., Diamond D.M., Gottschall P.E., et al. A β-peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 408:2000;982-985.
59. Dodart J.C., Bales K.R., Gannon K.S., et al. Immunization reverses memory deficits without reducing brain A beta burden in Alzheimer's disease model. Nat Neurosci. 5:2002;452-457.
60. Wyss-Coray T., Lin C., Yan F., et al. TGF-beta 1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat Med. 7:2001;612-618.
61. Backsai B., Kajdasz S., McKellen M., et al. Non-Fc-mediated mechanisms are involved in clearance of Amyloid-b in vivo by immunotherapy. J Neurosci. 22:2002;7873-7878.
62. Solomon B., Koppel R., Hanan E., et al. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proc Natl Acad Sci. 93:1996;452-455.
63. McLean C.A., Cherny R.A., Fraser F.W., et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol. 46:1999;860-866.
64. Koistinaho M., Ort M., Cimadevilla J.M., et al. Specific spatial learning deficits become severe with age in beta amyloid precursor protein transgenic mice that harbor diffuse beta amyloid deposits but do not form plaques. Proc Natl Acad Sci. 25:2001;14675-14680.
65. Schenk D. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nature. 3:2002;824-828.
66. Nicoll J.A.R., Wilkinson D., Holmes C., Steart P., Markham H., Weller R. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med. 9:2003;448-452.
67. Hock C., Konietzko U., Papassotiropoulos A., et al. Generation of antibodies specific for β-amyloid by vaccination of patients with Alzheimer disease. Nat Med. 11:2002;1270-1275.
68. Pfeifer M., Boncristiano S., Bondolfi L. Cerebral hemorrhage after passive anti-Abeta immunotherapy Science. 298:2002;1379.
69. Nicolau C., Greferath R., Balaban T.S. A liposome-based therapeutic vaccine against beta amyloid plaques on the pancreas of transgenic NORBA mice. Proc Natl Acad Sci. 99:2002;2332-2337.
70. Sigurdsson E.M., Scholtzova H., Mehta P.D., et al. Immunization with a nontoxic/nonfibrillar amyloid-β homologous peptide reduces Alzheimer's disease associated pathology in transgenic mice. Am J Pathol. 159:2001;439-447.
71. Frenkel D., Solomon B. Towards Alzheimer's beta-amyloid vaccination. Biologicals. 29:2001;243-247.
72. Sigurdsson E., Wisniewski T., Frangione B. A safer vaccine for Alzheimer's disease. Neurobiol Aging. 23:2002;1001-1008.
73. Soto C. Protein misfolding and disease; protein refolding and therapy. FEBS Lett. 498:2001;204-207.
74. Permanne B., Adessi C., Saborio G.P., et al. Reduction of amyloid load and cerebral damage in a transgenic mouse model of Alzheimer's disease by treatment with a beta-sheet breaker peptide. FASEB J. 16:2002;860-862.
75. Pepys M.B., Herbert J., Hutchinson W.L., et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature. 417:2002;254-259.
76. Tennent G.A., Lovat L.B., Pepys M.B. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer's disease and systemic amyloidosis. Proc Natl Acad Sci USA. 92:1995;4299-4303.
77. Atwood C.S., Moir R.D., Huang X., et al. Dramatic aggregation of Alzheimer Abeta by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem. 273:1998;12817-12826.
78. Atwood C.S., Scarpa R.C., Huang X., et al. Characterization of copper interactions with Alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta 1-42. J Neurochem. 75:2000;1219-1233.
79. Curtain C.C., Ali F., Volitakis I., et al. Alzheimer's disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J Biol Chem. 276:2001;20466-20473.
80. Lovell M.A., Robertson J.D., Teesdale W.J., et al. Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci. 158:1998;47-52.
81. Cherny R.A., Legg J.T., McLean C.A., et al. Aqueous dissolution of Alzheimer's disease: beta amyloid deposits by biometal depletion. J Biol Chem. 274:1999;23223-23228.
82. Cherny R.A., Atwood C.S., Xilinas M.E., et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron. 30:2001;665-676.
83. Yassin M.S., Ekblom J., Xilinas M., et al. Changes in uptake of vitamin B(12) and trace metals in brains of mice treated with clioquinol. J Neurol Sci. 173:2000;40-44.
84. Akiyama H., Barger S., Barnum S., et al. Inflammation and Alzheimer's disease. Neurobiol Aging. 21:2000;383-421.
85. McGeer P.L., Schulzer M., McGeer E.G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology. 47:1996;425-432.
86. Stewart W.F., Kawas C., Corrada M., et al. Risk of Alzheimer's disease and duration of NSAID use. Neurology. 48:1997;626-632.
87. In t'Veld B.A., Ruitenberg A., Hofman A., et al. Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer's disease. N Engl J Med. 345:2001;1515-1521.
88. Pasinetti G., Pompl P. Cyclo-oxygenase inhibitors and Alzheimer's: are we well ADAPTed? Lancet Neurology. 1:2002;403-404.
89. Meda L., Baron P.L., Scarlato G. Glial activation in Alzheimer's disease: the role of Abeta and its associated proteins. Neurobiol Aging. 22:2001;885-893.
90. Ho L., Purohit D., Haroutunian V., et al. Neuronal cyclooxygenase-2 expression in the hippocampal formation of the clinical progression of Alzheimer's disease. Arch Neurol. 58:2001;487-492.
91. Xiang Z., Ho L., Yemul S., et al. COX-2 promotes amyloid plaque deposition in a mouse model of Alzheimer's disease neuropathology. Gene Expression. 10:2002;271-278.
92. Lim G.P., Yang F., Chu T., et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci. 20:2000;5709-5714.
93. Weggen S., Eriksen J.L., Das P., et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature. 414:2001;212-216.
94. Jantzen P.T., Connor K.E., DiCarlo G., et al. Microglial activation and beta-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci. 22:2002;2246-2254.
95. Rogers J., Kirby L.C., Hempelman S.R., et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology. 43:1993;1609-1611.
96. Tabet N., Feldman H. Indomethacin for treatment of AD Patients (Cochrane review). The Cochrane Library. 2003;Update Software, Oxford. issue 2.
97. Aisen P.S., Schmeidler J., Pasinetti G.M., et al. Randomized pilot study of nimesulide treatment in Alzheimer's disease. Neurology. 58:2002;1050-1054.
98. Aisen P.S., Schafer K., Grundman M., et al. Results of a multicenter trial of rofecoxib and naproxen in Alzheimer's disease. Neurobiol Aging. 23:(suppl 1):2002;S429.
99. Sainati SM, Ingram DM, Talwalker, S, et al. Results of a double blind, randomized, placebo-controlled study of celecoxib in the treatment of progression of Alzheimer's disease. Proceedings of the Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy, Stockholm Sweden 2000: 180.
100. Block G., Norman B., Liu G., et al. A clinical trial of Rofecoxib, a selective COX-2 inhibitor, for the treatment of Alzheimer's disease. Neurobiol Aging. 23:2002;S73-S74.
101. Aisen P., Davis K.L., Berg J.D., et al. A randomized controlled trial of prednisone in Alzheimer's disease. Neurology. 54:2000;588-593.
102. Van Gool W.A., Weinstein H.C., Scheltens P.K., et al. Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomized, double-blind, placebo-controlled study. Lancet. 358:2001;455-460.
103. Aisen P. The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease. Lancet Neurol. 1:2002;279-284.
104. Dartigues J.F., Letenneur L. Genetic epidemiology of Alzheimer's disease. Curr Opin Neurol. 13:2000;385-389.
105. Sing C.F., Davignon J. Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am J Hum Genet. 37:1985;268-285.
106. Jarvik G.P., Wijsman E.M., Kukull W.A., et al. Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. Neurology. 45:1995;1092-1096.
107. Bales K., Verina T., Dodel R.C., et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet. 17:1997;263-264.
108. Holtzman D.M. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA. 97:2000;2892-2897.
109. Sparks D.L., Scheff S.W., Hunsaker J.C., et al. Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp Neurol. 126:1994;88-94.
110. Refolo L.M., Malester B., LaFrancois J., et al. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis. 7:2000;321-331.
111. Simons M., Keller P., De Strooper B., et al. Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons. Proc Natl Acad Sci USA. 95:1998;6460-6464.
112. Kojro E. Low cholesterol stimulates the non-amyloidogenic pathway by its effect on the α-secretase ADAM 10. Proc Natl Acad Sci USA. 98:2001;5815-5820.
113. Fassbender K. Simvastatin strongly reduces levels of Alzheimers disease β-amyloid peptides Aβ 42 and Aβ 40 in vitro and in vivo. Proc Natl Acad Sci USA. 98:2001;5856-5861.
114. Refolo L.M., Pappolla M.A., LaFrancois J., et al. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis. 8:2001;890-899.
115. Puglielli L., Konopka G., Pack-Chung E., et al. Acyl-coenzyme A: cholesterol acyltransferase (ACAT) modulates the generation of the amyloid β peptide. Nat Cell Biol. 3:2001;905-912.
116. Golde T.E., Eckman C.B. Cholesterol modulation as an emerging strategy for the treatment of Alzheimer's disease. Drug Discov Today. 20:2001;1049-1055.
117. Jick H. Statins and the risk of dementia. Lancet. 356:2000;1627-1631.
118. Wolozin B. Decreased prevalence of Alzheimer's disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol. 57:2000;1439-1443.
119. Shepherd J., Blauw G., Murphy M., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 360:2002;1623-1630.